Galectin-3: A Modifiable Risk Factor in Heart Failure

被引：59
|
作者：
de Boer, Rudolf A. [1 ,9 ]
van der Velde, A. Rogier [1 ]
Mueller, Christian [2 ]
van Veldhuisen, Dirk J. [1 ]
Anker, Stefan D. [3 ,4 ]
Peacock, W. Frank [5 ]
Adams, Kirkwood F. [6 ]
Maisel, Alan [7 ,8 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 GZ Groningen, Netherlands
[2] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland
[3] Charite, Dept Cardiol, D-13353 Berlin, Germany
[4] IRCCS San Raffaele, Ctr Clin & Basic Res, Rome, Italy
[5] Baylor Coll Med, Sect Emergency Med, Houston, TX 77030 USA
[6] Univ N Carolina, Div Cardiol, Chapel Hill, NC USA
[7] Univ Calif San Diego, Div Cardiol, La Jolla, CA 92093 USA
[8] San Diego Vet Affairs Med Ctr, San Diego, CA USA
[9] Univ Groningen, Med Ctr Groningen, Dept Cardiol, NL-9700 RB Groningen, Netherlands
来源：
CARDIOVASCULAR DRUGS AND THERAPY | 2014年 / 28卷 / 03期
基金：
瑞士国家科学基金会;
关键词：
Galectin-3; Biomarker; Heart failure; Cardiac remodeling; Fibrosis; PRESERVED EJECTION FRACTION; MODIFIED CITRUS PECTIN; PROGNOSTIC VALUE; HF-ACTION; FIBROSIS; INHIBITION; MARKER; MORTALITY; CANCER; MACROPHAGES;
D O I：
10.1007/s10557-014-6520-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Myocardial galectin-3 is upregulated upon cardiac stressors such as angiotensin II and pressure overload leading to cardiac remodeling and heart failure. The expression level of galectin-3 mirrors the progression and severity of heart failure and therefore, galectin-3 is being used as a biomarker for heart failure. However, as galectin-3 is causally involved in pathological myocardial fibrosis it has been suggested that galectin-3 also actively contributes to heart failure development. In this review we discuss how galectin-3 could be a target for therapy in heart failure. Currently, attempts are being made to target or inhibit galectin-3 using natural or pharmaceutical inhibitors with the aim to ameliorate heart failure. Available experimental evidence suggests that galectin-3 inhibition indeed may represent a novel tool to treat heart failure. A strong interaction with aldosterone, another strong pro-fibrotic factor, has been described. Clinical studies are needed to prove if galectin-3 may be used to install specific treatment regimens.
引用
收藏
页码：237 / 246
页数：10
相关论文
共 50 条
  • [1] Galectin-3: A Modifiable Risk Factor in Heart Failure
    Rudolf A. de Boer
    A. Rogier van der Velde
    Christian Mueller
    Dirk J. van Veldhuisen
    Stefan D. Anker
    W. Frank Peacock
    Kirkwood F. Adams
    Alan Maisel
    [J]. Cardiovascular Drugs and Therapy, 2014, 28 : 237 - 246
  • [2] Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites
    McEvoy, John W.
    Chen, Yuan
    Halushka, Marc K.
    Christenson, Eric
    Ballantyne, Christie M.
    Blumenthal, Roger S.
    Christenson, Robert H.
    Selvin, Elizabeth
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (05):
  • [3] The involvement of galectin-3 in heart failure
    Kalan, Maria
    Witczak, Agnieszka
    Mosiewicz, Jerzy
    Donica, Helena
    [J]. POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2015, 69 : 1107 - 1113
  • [4] The role of galectin-3 in heart failure
    Ricupati, F. Federica
    Novo, S. Salvatore
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 220 - 220
  • [5] Galectin-3 and Risk for Cancer or Heart Failure Does Sex Matter?
    Fabiani, Iacopo
    Chianca, Michela
    Emdin, Michele
    [J]. JACC: CARDIOONCOLOGY, 2023, 5 (04): : 454 - 456
  • [6] Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study
    Echouffo-Tcheugui, Justin B.
    Zhang, Sui
    Florido, Roberta
    Pankow, James S.
    Michos, Erin D.
    Goldberg, Ronald B.
    Nambi, Vijay
    Gerstenblith, Gary
    Post, Wendy S.
    Blumenthal, Roger S.
    Ballantyne, Christie M.
    Coresh, Josef
    Selvin, Elizabeth
    Ndumele, Chiadi E.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (06):
  • [7] Is galectin-3 a useful biomarker in stratifying the risk of heart failure in diabetes?
    Cuspidi, Cesare
    Gherbesi, Elisa
    Faggiano, Andrea
    [J]. JOURNAL OF CLINICAL ULTRASOUND, 2023, 51 (09) : 1436 - 1438
  • [8] Galectin-3 in cardiac remodeling and heart failure
    De Boer R.A.
    Yu L.
    Van Veldhuisen D.J.
    [J]. Current Heart Failure Reports, 2010, 7 (1) : 1 - 8
  • [9] Galectin-3 in different phenotypes of heart failure
    Hage, C. Camilla
    Bergman, A-C
    Estonius, M.
    Donal, E.
    Linde, C.
    Daubert, J-C
    Lund, L. H.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 492 - 493
  • [10] Metabolic Risk, Galectin-3 And Heart Failure: The Atherosclerosis Risk In Communities (aric) Study
    Tcheugui, Justin B. Echouffo
    Zhang, Sui
    Florido, Roberta
    Michos, Erin
    Nambi, Vijay
    Goldberg, Ronald B.
    Gerstenblith, Gary
    Post, Wendy S.
    Blumenthal, Roger S.
    Hoogeveen, Ron C.
    Coresh, Josef
    Folsom, Aaron R.
    Ballantyne, Christie M.
    Selvin, Elizabeth
    Ndumele, Chiadi E.
    [J]. CIRCULATION, 2021, 143
12345